Acumen Pharmaceuticals reported its third quarter 2024 financial results, highlighting a cash, cash equivalents, and marketable securities balance of $258.9 million as of September 30, 2024. This capital is expected to fund current clinical and operational activities into the first half of 2027. The company continues to incur operating losses as it invests in research and development.
Operationally, Acumen anticipates completing enrollment for its Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer’s disease in the first half of 2025. Additionally, topline results from the Phase 1 study supporting subcutaneous administration of sabirnetug are expected in the first quarter of 2025. These milestones are crucial for the advancement of sabirnetug.
The company's financial runway extending into the first half of 2027 provides funding through key data readouts, including the anticipated ALTITUDE-AD results. This financial stability supports the continued development of its lead therapeutic candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.